Medical Bulletin 18/April/2026 - Video

Here are the top medical news for today:

Study Examines Whether Processed Meats Can Be Included in a Healthy Diet

Is processed meat really the villain it’s made out to be—or is the story more complicated?

Processed meats like sausages, deli cuts, and cured products have long been part of human diets, valued for their convenience, shelf life, and rich nutrient profile. A recent perspective published in Animal Frontiers revisits their nutritional role, arguing that the debate around their health effects may not be as clear-cut as often portrayed.

From a nutritional standpoint, processed meats are a complete protein source, meaning they provide all nine essential amino acids required for muscle growth, tissue repair, and overall metabolic function. They also contain key micronutrients such as iron, zinc, and vitamin B12—nutrients that are either less abundant or less easily absorbed from plant-based foods. This makes them particularly valuable in populations at risk of nutrient deficiencies.

Processing methods such as curing, smoking, and fermentation are designed not just for flavor but also for safety and preservation. Ingredients like salt and nitrites help prevent bacterial growth and extend shelf life. While these additives are often viewed negatively, they serve important functional roles when used within regulated limits.

However, concerns remain. Many processed meats are high in sodium and saturated fats, both of which are linked to cardiovascular risks when consumed excessively. Public health guidelines in several countries recommend limiting intake, largely based on observational studies that associate processed meat consumption with chronic diseases.

In the end, the message is not to eliminate processed meats entirely, but to approach them with balance. When consumed in moderation and as part of a varied diet, they can still contribute meaningfully to nutrition—especially in settings where access to diverse, fresh foods is limited.

REFERENCE: Schilling, M. W., Smith, S. W., Apalowo, O. E., Comey, R., Wang, S., & Dinh, T. (2026). Processed meat in the diet: General nutritional profile, protein quality and micronutrients. Animal Frontiers. 16(1). 5,13. DOI: 10.1093/af/vfaf047 https://academic.oup.com/af/article/16/1/5/8382809

Researchers Explore Possible Link Between GLP-1 Drugs and Erectile Dysfunction

A popular diabetes drug may come with an unexpected trade-off—sexual health concerns in men.

Medications known as GLP-1 receptor agonists, widely used to manage Type 2 diabetes and support weight loss, are now being linked to a modest increase in the risk of erectile dysfunction (ED), according to a recent 2026 study using a target trial emulation design published in the Journal eClinicalMedicine.

Researchers analyzed electronic health records of over 10,000 men in the United States who had Type 2 diabetes and were newly started on either GLP-1 drugs or DPP-4 inhibitors. Importantly, men with a prior history of ED were excluded to better assess new-onset cases.

The findings showed that men taking GLP-1 medications had a slightly higher incidence of ED—about 35 cases per 1,000 person-years—compared to 28 cases in those using DPP-4 inhibitors. This translates to roughly a 26% increased risk over a three-year period. While the difference is not dramatic, it is notable given that ED already affects nearly half of men with Type 2 diabetes during their lifetime.

However, the picture is far from definitive. When researchers applied stricter statistical adjustments, the association weakened and was no longer clearly significant. This suggests that other factors—such as obesity, cardiovascular health, or lifestyle differences—may partly explain the findings.

Clinically, the results highlight the need for a more holistic approach to diabetes care. While GLP-1 drugs are highly effective for blood sugar control and weight reduction, doctors may need to discuss potential sexual health implications with patients, especially those already at risk.

At the same time, experts caution against jumping to conclusions. The study does not prove that GLP-1 drugs directly cause erectile dysfunction. More rigorous randomized trials are needed to clarify whether this link is real or simply a reflection of underlying health differences.

REFERENCE: Tang H et al. GLP-1 receptor agonist and risk of erectile dysfunction in men with Type 2 diabetes: a target trial emulation. EClinicalMedicine. 2026;DOI:10.1016/j.eclinm.2026.103857.

Scientists Identify Natural Hormone That May Reverse Obesity, Study Shows Promising Results

What if weight loss didn’t mean eating less—but burning more?

A new study suggests that a naturally occurring hormone could reshape how we treat obesity by targeting the brain’s energy-burning circuits rather than simply suppressing appetite. Researchers have found that Fibroblast Growth Factor 21, or FGF21, can reverse obesity in mice by activating a specific pathway in the brain that boosts metabolism.

Unlike popular weight-loss medications such as GLP-1 receptor agonists, which primarily work by reducing hunger and food intake, FGF21 appears to take a different route. It increases how much energy the body burns, essentially helping the body “use up” calories more efficiently.

The research, published in Cell Reports, revealed that FGF21 acts on the hindbrain—a region not traditionally associated with weight regulation. Scientists initially expected the hormone to signal the hypothalamus, the brain’s well-known appetite control center. Instead, they discovered that FGF21 targets areas in the hindbrain, including the nucleus of the solitary tract and the area postrema, which then communicate with other brain regions to regulate metabolism.

This newly identified brain circuit appears to be key to the hormone’s fat-burning effects. By activating this pathway, FGF21 can increase metabolic activity and reduce body weight without necessarily decreasing food intake. This makes it fundamentally different from current treatments and opens the door to alternative strategies for managing obesity.

The implications go beyond weight loss. FGF21-based therapies are already being explored for Metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease linked to obesity and metabolic dysfunction.

However, researchers caution that more studies are needed, especially in humans.

Still, this discovery highlights an exciting possibility: future obesity treatments may not just curb appetite but reprogram how the body burns energy at its core.

REFERENCE: Yunfan Lin, Kristin E. Claflin, Iltan Aklan, Donald A. Morgan, Andrew I. Sullivan, Michael C. Rudolph, Kamal Rahmouni, Matthew J. Potthoff. Pharmacological administration of FGF21 reverses obesity through a parabrachial-projecting neuron population in the hindbrain. Cell Reports, 2026; 45 (4): 117093 DOI: 10.1016/j.celrep.2026.117093